ClinicalTrials.gg
TerminatedNCT05315713Updated Oct 4, 2024Results posted

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

A Phase 1/2 interventional study of Mosunetuzumab SC and Tiragolumab in Non-Hodgkin Lymphoma, Follicular Lymphoma, sponsored by Hoffmann-La Roche. Terminated at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-04.

Primary conditionLymphoma, FollicularRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Follicular
Why
  1. The study's listed conditions name Lymphoma, Follicular, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to Sponsor decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing mosunetuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 3 of them phase 3. mosunetuzumab · Lymphoma, Follicular.

Enrollment
17th of 17
8 · median 42
Started
2022
with 5 others
Phase 1/2
2 of 17
none open now
Registered
5th of 17
by date
Lead sponsor
3 of 17
Hoffmann-La Roche

Among the 17 studies testing mosunetuzumab in Lymphoma, Follicular, this one is the 17th largest by enrollment, is one of 6 that started in 2022, is one of 2 in phase 1/2, and was the 5th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

8 of the 17 studies testing mosunetuzumab in Lymphoma, Follicular are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About mosunetuzumab

mosunetuzumab: first FDA approval 2022 (LUNSUMIO VELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing mosunetuzumab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who have received at least two previous lines of systemic therapy.

03

Conditions studied

  • Non-Hodgkin Lymphoma, Follicular Lymphoma

Browse trials for

Keywords

  • B-Cell Non-Hodgkin Lymphoma
04

In context

Lymphoma, Follicular Reclassified

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

This study's enrollment of 8 is below the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.

Browse Lymphoma, Follicular studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Compared within Lymphoma, Follicular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged >/= 18 years
  • (ECOG) performance status of 0, 1, or 2
  • of at least 12 weeks
  • documented FL or DLBCL that has or failed to respond to at least two prior systemic treatment regimens and for which no suitable therapy of curative intent or higher priority exists (e.g., standard chemotherapy, , CAR T cells)
  • At least one bi-dimensionally measurable (> 1.5 cm) nodal lesion, or at least one bi-dimensionally measurable (> 1.0 cm) extranodal lesion
  • Participants with FL (including trFL) for whom a bone marrow and aspirate can be collected
  • Adequate hematologic and organ function

Exclusion criteria

Exclusion Criteria:

  • Received any of the following treatments prior to study entry: mosunetuzumab or other CD20/CD3-directed bispecific antibodies; tiragolumab or other anti-TIGIT agent; allogenic SCT; solid organ transplantation
  • Currently eligible for SCT
  • Current or past history of CNS lymphoma or infiltration
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
  • to atezolizumab (if applicable) or tocilizumab
  • toxicities from prior treatment have not resolved to Grade \</= 1 (per v5.0) prior to the first study drug administration with exceptions defined by the protocol
  • Treatment-emergent immune-mediated adverse events associated with prior immunotherapeutic agents as defined by the protocol
  • Evidence of any significant, concomitant disease as defined by the protocol
  • Major surgery within 4 weeks prior to first study treatment administration, with the exception of protocol-mandated procedures (e.g., tumor and bone marrow biopsies)
  • Significant cardiac, pulmonary, CNS, or liver disease, or known active infections
  • History of other that could affect compliance with the protocol or interpretation of results
  • History of disease with exceptions as defined in the protocol
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Subcutaneous (SC) Mosunetuzumab in Combination with Intravenous (IV) Tiragolumab

    Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)

    Drug: Mosunetuzumab SC · Drug: Tiragolumab · Other: Tocilizumab

  • Experimental
    Mosunetuzumab SC in Combination with Tiragolumab IV and Atezolizumab IV

    Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days) Note: This arm did not enroll any participants.

    Drug: Mosunetuzumab SC · Drug: Tiragolumab · Drug: Atezolizumab · Other: Tocilizumab

Interventions

  • Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)

  • Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)

  • Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)

  • OtherTocilizumab

    Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events - Phase 1b

    Time frame: From the start of treatment until 90 days after the final dose of study treatment (up to 36 weeks)

  2. Best Objective Response Rate (ORR) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 2

    Time frame: Up to Cycle 17 (cycle length = 21 days)

Secondary outcomes

  1. Best ORR as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b

    Best ORR is defined as the fraction of participants with complete response (CR) or partial response (PR) at any time as determined by the investigator using Lugano 2014 criteria.

    Time frame: Assessed at screening and then every 3-6 months until disease progression, start of new anti-cancer therapy, or withdrawal (through Cycle 8; cycle length = 21 days)

  2. Serum Concentration of Mosunetuzumab - Phase 1b

    Time frame: Cycle 1 Day 1 - Cycle 8 Day 1 (cycle length = 21 days)

  3. Best Complete Response (CR) Rate as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b

    Time frame: Assessed at screening and then every 3-6 months until disease progression, start of new anti-cancer therapy, or withdrawal (through Cycle 8; cycle length = 21 days)

  4. Duration of Response (DOR) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b and Phase 2

    Time frame: From the first occurrence of a documented response (CR or partial response (PR)) to disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 4 years)

  5. Progression-Free Survival (PFS) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 2

    Time frame: From the first study treatment to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 4 years)

  6. Event-Free Survival (EFS) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 2

    Time frame: From the first study treatment to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 4 years)

  7. Overall Survival (OS) - Phase 2

    Time frame: From the time of first study treatment to death from any cause (up to approximately 4 years)

  8. Percentage of Participants With Adverse Events - Phase 2

    Time frame: From the start of treatment until 90 days after the final dose of study treatment

08

Results

Posted Oct 4, 2024
Limitations and caveats
Early termination led to small numbers of participants for analysis.

Participant flow

Participant flow — Overall Study
MilestoneSubcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
Started8
Completed0
Not completed8
Withdrew: Death5
Withdrew: Progressive disease1
Withdrew: Withdrawal by subject1
Withdrew: Study terminated by sponsor1

Outcome measures

PrimaryPercentage of Participants With Adverse Events - Phase 1b
Time frame:
From the start of treatment until 90 days after the final dose of study treatment (up to 36 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events - Phase 1b
Percentage of participantsSubcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
Percentage of Participants With Adverse Events - Phase 1b100
PrimaryBest Objective Response Rate (ORR) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 2
Time frame:
Up to Cycle 17 (cycle length = 21 days)

No measurements were reported for this outcome.

SecondaryBest ORR as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b

Best ORR is defined as the fraction of participants with complete response (CR) or partial response (PR) at any time as determined by the investigator using Lugano 2014 criteria.

Time frame:
Assessed at screening and then every 3-6 months until disease progression, start of new anti-cancer therapy, or withdrawal (through Cycle 8; cycle length = 21 days)
Reported as:
Number · Percentage of participants
Best ORR as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b
Percentage of participantsSubcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
Best ORR as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b62.5
SecondarySerum Concentration of Mosunetuzumab - Phase 1b
Time frame:
Cycle 1 Day 1 - Cycle 8 Day 1 (cycle length = 21 days)
Reported as:
Geometric mean · ug/mL
Serum Concentration of Mosunetuzumab - Phase 1b
ug/mLSubcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
C1D1 pre-doseNA ± NA
C1D1 3 hrs post-dose0.00983 ± NA
C1D2 24 hrs post-dose0.0556 ± 109.6
C1D4 72 hrs post-dose0.164 ± 90.5
C1D8 pre-dose0.166 ± 83.2
C1D15 pre-dose2.18 ± 48.8
C2D1 pre-dose4.02 ± 86.3
C3D1 pre-dose2.90 ± 81.8
C4D1 pre-dose2.34 ± 49.0
C4D1 3 hrs post-dose2.10 ± 48.2
C5D1 pre-dose2.59 ± 25.7
C8D1 pre-dose2.97 ± 17.7
SecondaryBest Complete Response (CR) Rate as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b
Time frame:
Assessed at screening and then every 3-6 months until disease progression, start of new anti-cancer therapy, or withdrawal (through Cycle 8; cycle length = 21 days)
Reported as:
Number · Percentage of participants
Best Complete Response (CR) Rate as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b
Percentage of participantsSubcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
Best Complete Response (CR) Rate as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b37.5
SecondaryDuration of Response (DOR) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b and Phase 2
Time frame:
From the first occurrence of a documented response (CR or partial response (PR)) to disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 4 years)
Reported as:
Number · Time
Duration of Response (DOR) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b and Phase 2
TimeSubcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
Duration of Response (DOR) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b and Phase 2NA
SecondaryProgression-Free Survival (PFS) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 2
Time frame:
From the first study treatment to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 4 years)

No measurements were reported for this outcome.

SecondaryEvent-Free Survival (EFS) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 2
Time frame:
From the first study treatment to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 4 years)

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) - Phase 2
Time frame:
From the time of first study treatment to death from any cause (up to approximately 4 years)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Adverse Events - Phase 2
Time frame:
From the start of treatment until 90 days after the final dose of study treatment

No measurements were reported for this outcome.

Adverse events

Collected over From the start of treatment until 90 days after the final dose of study treatment (up to 36 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab5/8 (62.5%)2/8 (25%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventSubcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
Abdominal painGastrointestinal disorders1/8
DiarrhoeaGastrointestinal disorders1/8
COVID-19Infections and infestations1/8
Pneumonia aspirationInfections and infestations1/8
Septic shockInfections and infestations1/8
FallInjury, poisoning and procedural complications1/8
Cerebellar haematomaNervous system disorders1/8
Most frequent other events
Showing 10 of 49
Most frequent other events
EventSubcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
AnaemiaBlood and lymphatic system disorders3/8
Injection site reactionGeneral disorders3/8
DyspnoeaRespiratory, thoracic and mediastinal disorders3/8
NeutropeniaBlood and lymphatic system disorders2/8
ConstipationGastrointestinal disorders2/8
NauseaGastrointestinal disorders2/8
AstheniaGeneral disorders2/8
Oedema peripheralGeneral disorders2/8
HypokalaemiaMetabolism and nutrition disorders2/8
HypophosphataemiaMetabolism and nutrition disorders2/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
Mean64.9 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
Female4
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race0
Unknown or Not Reported2
09

Study locations

17 sites
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Lifespan Cancer Institute
    Providence, Rhode Island 02905, United States
  • St Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Eastern Health
    Box Hill, Victoria, Australia
  • St Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • AZ Sint Jan Brugge Oostende AV
    Brugge, 8000, Belgium
  • Institut Jules Bordet
    Bruxelles, 1000, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • CHU UCL Namur - Mont-Godinne
    Yvoir, 5530, Belgium
  • Tom Baker Cancer Centre-Calgary
    Calgary, Alberta T2N 4N2, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 1Z5, Canada
  • Universitaet Duisburg-Essen
    Essen, 45122, Germany
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • Royal Marsden Hospital - Institute of Cancer Research - Chelsea
    London, SE3 6JJ, United Kingdom
  • Plymouth Hospitals NHS Trust - Derriford Hospital
    Plymouth, United Kingdom
  • Royal Marsden Hospital - Institute of Cancer Research - Sutton
    Sutton, SM2 5PT, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Jul 2023, 14 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2022
First posted
Apr 7, 2022
StartActual
May 10, 2022
Primary completionActual
Jul 19, 2023
CompletionActual
Jul 19, 2023
Results first posted
Oct 4, 2024
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05315713
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 7, 2022
Start date
May 10, 2022
Primary completion
Jul 19, 2023
Completion
Jul 19, 2023
Results posted
Oct 4, 2024
Last update
Oct 4, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mosunetuzumab · Tiragolumab

Start the discussion